Lacticaseibacillus Casei

OTHER NAME(S): L. casei, Lactobacillus casei, Lacticaseibacillus casei

Overview

Lacticaseibacillus casei (L. casei) is a probiotic bacteria that is available over the counter as a supplement and in various fermented foods. It is commonly used to improve the health of the gut and immune system, but its benefits are not well defined. Common side effects include gas and an upset stomach. Serious side effects are rare and include infections in some people who are at high risk of infections. Before taking L. casei, make sure to tell your health care provider about any health conditions you have or medicines you are taking.

References
  1. American Journal of Clinical Nutrition: “Efficacy of daily intake of Lactobacillus casei Shirota on respiratory symptoms and influenza vaccination immune response: A randomized, double-blind, placebo-controlled trial in healthy elderly nursing home residents.”
  2. European Journal of Applied Physiology: “Effects of Lactobacillus casei Shirota ingestion on common cold infection and herpes virus antibodies in endurance athletes: A placebo-controlled, randomized trial.”
  3. Journal of Pediatric Gastroenterology and Nutrition: “Lactobacilli and Bifidobacteria in human breast milk: influence of antibiotherapy and other host and clinical factors.”
  4. National Center for Complementary and Integrative Health: “5 Things To Know About Probiotics,” “Probiotics: Usefulness and Safety.”
  5. National Institutes of Health Office of Dietary Supplements: “Probiotics Fact Sheet for Consumers,” “Probiotics Fact Sheet for Health Professionals.”
  6. Nutrients: “A double-blind, randomized placebo-controlled trial of probiotic Lactobacillus casei Shirota in stable cirrhotic patients,” “A pilot study of the effect of Lactobacillus casei obtained from long-lived elderly on blood biochemical, oxidative, and inflammatory markers, and on gut microbiota in young volunteers,” “Probiotic Lactobacillus casei: Effective for managing childhood diarrhea by altering gut microbiota and attenuating fecal inflammatory markers.”
  7. FDA: “FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants.”